Prostate Cancer ADT Linked to Higher Risk of Liver Diseases

Men who undergo androgen deprivation therapy (ADT) for prostate cancer (PCa) are at elevated risk of developing non-alcoholic fatty liver disease and other liver diseases, a study found.

Compared with PCa patients who did not receive ADT, those who did had a 54% increased risk of being diagnosed with non-alcoholic fatty liver disease, in analyses that included propensity score adjustment, researchers led by Quoc-Dien Trinh, MD, of Brigham and Women’s Hospital in Boston, reported in The Journal of Urology.

Source: RENAL & UROLOGY NEWS